Pfizer (NYSE: PFE) invalidates two GSK RSV vaccine patents in U.K.

Pfizer (NYSE: PFE) secured a victory in a U.K. court on Monday, successfully invalidating two of GSK’s (GSK) patents related to a respiratory syncytial virus (RSV) vaccine.

Both Pfizer and GSK, along with several other companies, are competing to develop a vaccine for RSV, a virus that usually causes cold-like symptoms but is a major cause of pneumonia in young children and the elderly.